Amgen Inc.’s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

U.S. equities were mixed at midday following comments from President-elect Trump about new tariffs on Chinese, Canadian, and ...

Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...

Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.

Stocks are shrugging off a new Trump tariff threat as the President-elect vows sweeping levies on the biggest U.S. trading ...